Abstracts tagged "B-Lymphocyte"

Abstract Number: 1502 • ACR Convergence 2021
Longitudinal Changes in B Cell Subsets in Patients in the Mesenchymal Stromal Cell Trial in Lupus: Analysis of the First Cohort
Diane Kamen¹, S Sam Lim², Scott Jenks³, Regina Bugrovosky³, Aisha Hill³, Chungwen Wei³, Cristina Drenkard³, Kenneth Kalunian⁴, Ummara Shah⁵, Mariko Ishimori⁶, Rosalind Ramsey-Goldman⁷, Saira Sheikh⁸, Mary Alison Mahieu⁷, Daniel Wallace⁹, Ellen Goldmuntz¹⁰ and Gary Gilkeson¹, ¹Medical University of South Carolina, Charleston, SC, ²Department of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, GA, ³Emory University, Atlanta, GA, ⁴UC San Diego, La Jolla, CA, ⁵University of Rochester, Rochester, NY, ⁶Cedars-Sinai Health System, Los Angeles, CA, ⁷Northwestern University, Chicago, IL, ⁸University of North Carolina, Chapel Hill, NC, ⁹Attune Health, Beverly Hills, CA, ¹⁰National Institutes of Health, Bethesda, MD
Background/Purpose: Recent advances allow expanded identification of B cell subtypes of pathogenic potential in lupus. Of particular interest are IgD- CD27- double negative (DN2) B…
Abstract Number: 0008 • ACR Convergence 2021
Jo-1-Binding and Clonally-Expanded Memory B Cells Express Germline and Somatically-Mutated B Cell Receptors in Anti-tRNA Synthetase Syndrome Patients
Erin Wilfong, Alberto Cisneros, Jennifer Young-Glazer, Scott Smith, Leslie Crofford and Rachel Bonami, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Anti-tRNA synthetase syndrome (ARS) is a severe systemic autoimmune disease associated with myositis, interstitial lung disease, rash, and arthritis. ARS is associated with autoantibodies…
Abstract Number: 1905 • ACR Convergence 2021
CD11c+ Expression Associates with IFN-λ Responsiveness in Human B Cells with Clinical Implications for SLE
Jennifer Barnas¹, Jennifer Barnard², Cameron Baker², Nida Meednu², Andrew McDavid¹, R. John Looney¹ and Jennifer Anolik², ¹University of Rochester, Rochester, NY, ²University of Rochester Medical Center, Rochester, NY
Background/Purpose: Type I interferon (IFN), namely IFN- α, and B cell aberrations are long recognized in systemic lupus erythematosus (SLE) pathogenesis. Type I IFN receptor…
Abstract Number: 0010 • ACR Convergence 2021
Relaxed Peripheral Tolerance Drives Broad de Novo Autoreactivity in Severe COVID-19
Matthew Woodruff¹, Richard Ramonell², Ankur Singh Saini², Mark Rudolph³, F. Eun-Hyung Lee² and Iñaki Sanz⁴, ¹Emory University, Decatur, GA, ²Emory University, Atlanta, GA, ³Exagen Inc., Vista, CA, ⁴Emory University School of Medicine, Atlanta, GA
Background/Purpose: An emerging feature of COVID-19 is the identification of autoreactivity in patients with severe disease that may contribute to disease pathology, however the origins…
Abstract Number: 1907 • ACR Convergence 2021
Increased Otoferlin Expression in B Cells Is Associated with Muscle Weakness in Untreated Juvenile Dermatomyositis: A Pilot Study
Ameera Bukhari¹, Amer Khojah², Wilfredo Marin³, Gabrielle Morgan⁴ and Lauren Pachman⁵, ¹Department of Microbiology and Immunology, Loyola University Chicago, Chicago, IL, ²Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ³Ann & Robert H. Lurie Children's Hospital, Chicago, IL, ⁴Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵Northwestern's Feinberg School of Medicine. Ann and Robert H. Lurie Children's Hospital of Chicago; Stanley Manne Children's Research Institute of Chicago, Lake Forest, IL
Background/Purpose: Juvenile Dermatomyositis (JDM) is a rare pediatric inflammatory myopathy with a complex pathophysiology. Previously our group showed a significant increase in Otoferlin mRNA expression…
Abstract Number: 0321 • ACR Convergence 2021
Sequential Administration of Belimumab and Rituximab in Primary Sjögren’s Syndrome Reduces Minor Salivary Gland–Resident B Cells and Delays B-Cell Repopulation in Circulation
André van Maurik¹, David Gardner², Saba Nayar², Charlotte Smith², Kenneth Clark¹, Prafull Mistry¹, Rajesh Punwaney³, David Roth³, Robert Henderson¹, Xavier Mariette⁴ and Francesca Barone², ¹GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom, ²University of Birmingham, College of Medical and Dental Sciences, Birmingham, United Kingdom, ³GlaxoSmithKline, Collegeville, PA, ⁴Université Paris- Saclay, Rheumatology, Paris, France
Background/Purpose: Primary Sjögren’s syndrome (pSS) is characterized by B-cell hyperactivity and elevated serum and saliva B-lymphocyte stimulator (BLyS) levels.1 Sequential administration of belimumab (BEL; anti-BLyS)…
Abstract Number: 0322 • ACR Convergence 2021
Histopathological Changes in Parotid and Labial Salivary Gland Tissue in Primary Sjögren’s Syndrome Patients After Abatacept Treatment
Uzma Nakshbandi¹, Liseth de Wolff², Frans Kroese¹, Silvia Liefers³, Neelanjana Ray⁴, Gwenny Verstappen¹, Fred Spijkervet³, Marleen Nys⁵, Arjan Vissink⁶, Robert Wong⁷, Bert van der vegt³ and Hendrika Bootsma¹, ¹University Medical Center Groningen, Groningen, Netherlands, ²University Medical Centre Groningen, Groningen, Netherlands, ³University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁴Bristol-Myers Squibb Company, Lawrenceville, GA, ⁵Bristol Myers Squibb, Braine-l'Alleud, Belgium, ⁶University of Groningen, University Medical Center Groningen, Leek, Netherlands, ⁷Bristol Myers Squibb, Basking Ridge, NJ
Background/Purpose: In a previous open-label phase II study, we showed that abatacept treatment might inhibit local formation of autoreactive memory B cells in parotid glands…
Abstract Number: 0416 • ACR Convergence 2021
Pharmacological Response of Rituximab Based on Dose Intensity in Maintenance Therapy of ANCA-Associated Vasculitis
Jason Springer¹ and Ryan Funk², ¹Vanderbilt University Medical Center, Franklin, TN, ²University of Kansas Medical Center, Kansas City, KS
Background/Purpose: Rituximab (RTX) has demonstrated efficacy in maintenance therapy in ANCA-associated vasculitis. However, different dosing protocols have been used in clinical trials and there is…
Abstract Number: 0778 • ACR Convergence 2020
Bacterial Families Lachnospiraceae/Ruminococcaceae Are Immunologically Targeted in Individuals At-risk for RA and a Specific Strain Is Arthritogenic in Monocultured Gnotobiotic Mice
Meagan Chriswell¹, Jennifer Seifert², Lisa Blum³, Michelle Bloom³, Marie Feser⁴, M Kristen Demoruelle⁵, Jill Norris⁶, Kevin D. Deane⁷, Eddie James⁸, Jane Buckner⁸, William Robinson³, V. Michael Holers⁵ and Kristine Kuhn⁹, ¹UC Denver SOM, Denver, CO, ²UC Denver, Littleton, CO, ³Stanford University, Palo Alto, CA, ⁴Division of Rheumatology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA, Colorado, ⁵University of Colorado, Denver, CO, ⁶Colorado School of Public Health, Aurora, CO, ⁷2 Division of Rheumatology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA, Colorado, ⁸Center for Translational Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁹University of Colorado Anschutz Medical Campus, Aurora, CO
Background/Purpose: Circulating autoantibodies, including anti-CCP and RF, develop years before physical manifestations of rheumatoid arthritis (RA), with several lines of evidence suggesting that these autoantibodies…
Abstract Number: 1455 • ACR Convergence 2020
Functional Characterization of PLCG2 Mutations Found in Subjects with Autoinflammation and PLCG2-Associated Antibody Deficiency and Immune Dysregulation (APLAID) Reveals Both Hypermorphic and Hypomorphic Mutants
Kathleen Baysac¹, Charles Fisher², Hiroto Nakano², Joshua Milner³ and Michael Ombrello⁴, ¹NIAMS, NIH, Bethesda, MD, ²NIAMS, NIH, Bethesda, ³Division of Allergy, Immunology and Rheumatology Columbia University Medical Center, New York, NY, ⁴Translational Genetics and Genomics Unit, NIAMS, NIH, Bethesda, MD
Background/Purpose: PLCG2-associated antibody deficiency and immune dysregulation (PLAID) and autoinflammatory PLAID (APLAID) are autosomal dominant diseases caused by mutations of PLCG2. APLAID is clinically characterized by episodic…
Abstract Number: 0851 • ACR Convergence 2020
Iberdomide Decreases B Cells and Plasmacytoid Dendritic Cells, Increases Regulatory T Cells and IL-2, and Has Enhanced Clinical Efficacy in Active Systemic Lupus Erythematosus Patients with High Aiolos or the IFN Gene Expression Signature
Peter Lipsky¹, Ronald van Vollenhoven², Thomas Dörner³, Victoria Werth⁴, Joan Merrill⁵, Richard Furie⁶, Milan Petronijevic⁷, Benito Velasco Zamora⁸, Maria Majdan⁹, Fedra Irazoque-Palazuelos¹⁰, Robert Terbrueggen¹¹, Nikolay Delev¹², Michael Weiswasser¹², Shimon Korish¹², Nataliya Agafonova¹², Mark Stern¹³, Sarah Hersey¹³, Ying Ye¹³, Allison Gaudy¹², Zhaohui Liu¹², Shaojun Tang¹³ and Peter Schafer¹², ¹RILITE Foundation, Charlottesville, VA, ²Amsterdam University Medical Centers, Amsterdam, Netherlands, ³DRFZ and Charité University Hospitals, Berlin, Germany, ⁴University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, PA, ⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ⁷Military Medical Academy, Belgrade, Serbia, ⁸Instituto CER S.A., Buenos Aires, Argentina, ⁹Medical University of Lublin and Samodzielny Publicnzy Szpital Kliniczny Nr 4 w Lublinie, Lublin, Poland, ¹⁰Centro de Investigación y Tratamiento Reumatológico S.C, Miguel Hidalgo, Mexico, ¹¹DxTerity Diagnostics Inc, Rancho Dominguez, ¹²Bristol Myers Squibb, Princeton, ¹³Bristol-Myers Squibb, Princeton
Background/Purpose: Iberdomide is a high-affinity cereblon ligand that promotes ubiquitination and proteasomal degradation of Ikaros (IKZF1) and Aiolos (IKZF3), transcription factors linked to the genetic…
Abstract Number: 1456 • ACR Convergence 2020
Exploring the RA Bone Marrow Niche by Single-cell Technology to Identify Long Lived ACPA+ Plasma Cells
Khaled Amara¹, Aase Hensvold², Radha Thyagarajan¹, Lena Israelsson¹, Johanna Steen¹, Heidi Wähämaa¹, Monika Hansson¹, Marianne Engström¹, Annika van Vollenhoven¹, Anca Catrina², Vivianne Malmström³ and Caroline Grönwall¹, ¹Karolinska Institutet, Stockholm, Sweden, ²Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, Stockholm, Stockholms Lan, Sweden, ³Karolinska Institutet, Stockholm, Stockholms Lan, Sweden
Background/Purpose: Autoantibodies is a hallmark of rheumatoid arthritis, placing the adaptive immune system and B-cells centrally in the pathogenesis. The anti-citrullinated autoantibodies (ACPA) detected in…
Abstract Number: 0859 • ACR Convergence 2020
Biomarkers of B-cell Depletion and Response in a Randomized, Controlled Trial of Obinutuzumab for Proliferative Lupus Nephritis
Ed Vital¹, Philippe Remy², Luis Fernando Quintana Porras³, Laurent Chiche⁴, Dominique Chauveau⁵, Richard Furie⁶, Thomas Schindler⁷, Jay Garg⁸, Matthew Cascino⁸, Zahir Amoura⁹, Andrea Doria¹⁰, Cary Looney⁸ and Dario Roccatello¹¹, ¹University of Leeds; NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ²APHP Groupe Hospitalier Henri-Mondor, Creteil, France, ³Hospital Clinic de Barcelona, Barcelona, Catalonia, Spain, ⁴Hôpital Européen, Marseille, France, ⁵Hôpital Rangueil, Centre Hospitalier Univ de Toulouse, Toulouse, France, ⁶Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ⁷F. Hoffmann-La Roche Ltd., Basel, Switzerland, ⁸Genentech, Inc., South San Francisco, CA, ⁹Hôpital Pitié-Salpêtrière, Paris, ¹⁰University of Padua, Padua, Italy, ¹¹S Giovanni Hospital, Univ of Turin, Turin, Italy
Background/Purpose: Incomplete B-cell and plasmablast depletion, as measured using highly sensitive flow cytometry (HSFC), is associated with lower response rates following rituximab in SLE [1].…
Abstract Number: 1480 • ACR Convergence 2020
Abatacept for the Treatment of IgG4-Related Disease
Mark Matza¹, Cory Perugino¹, Liam Harvey², Zachary Wallace³, Hang Liu⁴, Shiv Pillai⁵ and John H. Stone⁶, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, ³Massachusetts General Hospital, Newton, MA, ⁴Massachusetts General Hospital, Cambridge, MA, ⁵Harvard Medical School, Cambridge, MA, ⁶Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Background/Purpose: To assess the efficacy and safety of abatacept (ABA) for the treatment of IgG4-related disease (IgG4-RD). To date, there are no FDA-approved treatments available…
Abstract Number: 0948 • ACR Convergence 2020
Mass Cytometry Reveals Activation Heterogeneity of Circulating Neutrophils in Systemic Lupus Erythematosus
Ricardo Grieshaber-Bouyer¹, Joshua Keegan², Peter Nigrovic³, James Lederer⁴ and Deepak Rao², ¹Department of Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany; Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA, Heidelberg, Germany, ²Brigham and Women's Hospital, Boston, MA, ³Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA, Boston, ⁴BWH Harvard Medical School, Boston, MA
Background/Purpose: Neutrophils are important effector cells in systemic immune-mediated diseases. Neutrophil phenotypes vary depending on their age, maturity, activation state, and local environment; however, differences…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.